253 related articles for article (PubMed ID: 32301565)
21. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia.
Gadeyne C; Little P; King VL; Edwards N; Davis K; Stegemann MR
Vet Dermatol; 2014 Dec; 25(6):512-8, e86. PubMed ID: 25109820
[TBL] [Abstract][Full Text] [Related]
22. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial.
Olivry T; Rivierre C; Jackson HA; Murphy KM; Davidson G; Sousa CA
Vet Dermatol; 2002 Apr; 13(2):77-87. PubMed ID: 11972891
[TBL] [Abstract][Full Text] [Related]
23. Weekly topical therapy based on plant extracts combined with lokivetmab in canine atopic dermatitis.
Bensignor E; Videmont E
Vet Dermatol; 2022 Feb; 33(1):68-e22. PubMed ID: 34414621
[TBL] [Abstract][Full Text] [Related]
24. Are transepidermal water loss and clinical signs correlated in canine atopic dermatitis? A compilation of studies.
Marsella R
Vet Dermatol; 2012 Jun; 23(3):238-e49. PubMed ID: 22575022
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.
Cosgrove SB; Wren JA; Cleaver DM; Martin DD; Walsh KF; Harfst JA; Follis SL; King VL; Boucher JF; Stegemann MR
Vet Dermatol; 2013 Oct; 24(5):479-e114. PubMed ID: 23829933
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response.
Carrasco I; Ferrer L; Puigdemont A
J Feline Med Surg; 2022 Aug; 24(8):787-793. PubMed ID: 34612749
[TBL] [Abstract][Full Text] [Related]
27. Clinical use of a ceramide-based moisturizer for treating dogs with atopic dermatitis.
Jung JY; Nam EH; Park SH; Han SH; Hwang CY
J Vet Sci; 2013; 14(2):199-205. PubMed ID: 23814473
[TBL] [Abstract][Full Text] [Related]
28. Speed of onset of a new chewable formulation of oclacitinib maleate (Apoquel®) in a canine model of IL-31-induced pruritus.
Fleck T; Norris L; King V; Lesman S; Gonzales AJ
J Vet Pharmacol Ther; 2022 Jul; 45(4):380-384. PubMed ID: 35586953
[TBL] [Abstract][Full Text] [Related]
29. Pilot evaluation of Enterococcus faecium SF68 as adjunctive therapy for oclacitinib-responsive adult atopic dermatitis in dogs.
Yamazaki C; Rosenkrantz W; Griffin C
J Small Anim Pract; 2019 Aug; 60(8):499-506. PubMed ID: 31257599
[TBL] [Abstract][Full Text] [Related]
30. Onset and duration of action of lokivetmab in a canine model of IL-31 induced pruritus.
Fleck TJ; Norris LR; Mahabir S; Walters RR; Martinon O; Dunham SA; Gonzales AJ
Vet Dermatol; 2021 Dec; 32(6):681-e182. PubMed ID: 33830571
[TBL] [Abstract][Full Text] [Related]
31. A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood-induced hypersensitivity dermatitis.
Noli C; Matricoti I; Schievano C
Vet Dermatol; 2019 Apr; 30(2):110-e30. PubMed ID: 30656750
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulatory effect of long-term oclacitinib maleate therapy in dogs with atopic dermatitis.
De Caro Martins G; da Costa-Val AP; Coura FM; Diamantino GML; Nogueira MM; de Oliveira Melo-Junior OA; Giunchetti RC; da Silveira-Lemos D; Melo MM
Vet Dermatol; 2022 Apr; 33(2):142-e40. PubMed ID: 34747068
[TBL] [Abstract][Full Text] [Related]
33. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis.
Michels GM; Walsh KF; Kryda KA; Mahabir SP; Walters RR; Hoevers JD; Martinon OM
Vet Dermatol; 2016 Dec; 27(6):505-e136. PubMed ID: 27647513
[TBL] [Abstract][Full Text] [Related]
34. Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis.
Steffan J; Parks C; Seewald W;
J Am Vet Med Assoc; 2005 Jun; 226(11):1855-63. PubMed ID: 15934253
[TBL] [Abstract][Full Text] [Related]
35. The influence of non-specific anti-pruritus treatment with cyclosporine A on transepidermal water loss (TEWL) in natural atopic dermatitis in dogs.
Zając M; Szczepanik M; Wilkołek P; Adamek Ł; Pomorski Z
Pol J Vet Sci; 2015; 18(2):415-24. PubMed ID: 26172193
[TBL] [Abstract][Full Text] [Related]
36. A randomized double-blind clinical trial: Comparison of oclacitinib with a traditional Chinese herbal medicine product (Dihuang Guiqin capsule) in the treatment of canine atopic dermatitis.
Qin JJ; Zhu H; Song ZW; Hou XJ; Wang XM; Wang L; Li JX
Res Vet Sci; 2024 May; 171():105221. PubMed ID: 38490043
[TBL] [Abstract][Full Text] [Related]
37. Topical treatment with SPHINGOLIPIDS and GLYCOSAMINOGLYCANS for canine atopic dermatitis.
Marsella R; Segarra S; Ahrens K; Alonso C; Ferrer L
BMC Vet Res; 2020 Mar; 16(1):92. PubMed ID: 32197613
[TBL] [Abstract][Full Text] [Related]
38. A randomized, double-blind, placebo-controlled study to evaluate the effect of EFF1001, an Actinidia arguta (hardy kiwi) preparation, on CADESI score and pruritus in dogs with mild to moderate atopic dermatitis.
Marsella R; Messinger L; Zabel S; Rosychuck R; Griffin C; Cronin PO; Belofsky G; Lindemann J; Stull D
Vet Dermatol; 2010 Feb; 21(1):50-7. PubMed ID: 19843302
[TBL] [Abstract][Full Text] [Related]
39. Measurement of serum Interleukin 34 (IL-34) and correlation with severity and pruritus scores in client-owned dogs with atopic dermatitis.
Gow DJ; Jackson H; Forsythe P; Nuttall T; Gow AG; Mellanby RJ; Hume DA
Vet Dermatol; 2020 Oct; 31(5):359-e94. PubMed ID: 32794277
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a human generic formulation of ciclosporin in the treatment of canine atopic dermatitis with in vitro assessment of the functional capacity of phagocytic cells.
Kovalik M; Taszkun I; Pomorski Z; Kozak M; Pomorska D; Szczepanik M; Wilkolek P; Palenik L; Shaw DJ; van den Broek AH; Thoday KL
Vet Rec; 2011 May; 168(20):537. PubMed ID: 21558130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
